PharmAthene investors breathe easier after FDA lifts SparVax hold
This article was originally published in Scrip
Executive Summary
Shares of biodefense company PharmAthene soared 16% in morning trading on 30 May on word the US FDA has lifted its clinical hold on the Annapolis, Maryland-based biotech's proposed Phase II study of its next-generation recombinant protective antigen (rPA) anthrax vaccine SparVax.